Opioid Addiction | Disease Landscape and Forecast | G7 | 2017
The few currently available pharmacological treatments for opioid addiction fall into one of two categories: substitution therapies or abstinent therapies. Substitution therapies (i.e., methadone, buprenorphine, and buprenorphine/naloxone combination) prevent a patient from experiencing withdrawal symptoms but allow the patient to still experience a limited “high” without taking any illicit opioids. Abstinent therapies (i.e., naltrexone) block the euphoric effect of opioids if a patient attempts to take an illicit opioid while on abstinent therapy. In most markets, regardless of which type of opioid addiction treatment received, relapse rates among opioid addicts remain high. Thus, commercial opportunity exists for new opioid addiction treatments, particularly those that can more effectively reduce the craving and opioid use and do not have an abuse potential.
Questions Answered:
- How is opioid addiction currently treated in the major pharmaceutical markets? What are interviewed experts’ opinions of current opioid addiction therapies?
- What are the greatest unmet needs in terms of treating opioid addiction and to what extent will these needs be fulfilled in the next ten years?
- What do interviewed experts think about late-phase emerging therapies such as long-acting depot buprenorphine products from Camurus/Braeburn Pharmaceuticals (CAM-2038) and Indivior (RBP-6000)?
- What is the commercial potential of late-phase pipeline products in the opioid addiction market should they launch?
Product Description:
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
